Core Viewpoint - Appili Therapeutics Inc. has formally terminated its arrangement agreement with Aditxt Inc. and is entitled to a termination fee of USD 1,250,000, with USD 1,000,000 remaining payable after adjustments [1][2]. Group 1: Termination of Arrangement Agreement - The termination of the arrangement agreement with Aditxt is effective as of May 30, 2025 [1]. - Appili is entitled to a termination fee of USD 1,250,000, which has been reduced by previous payments made by Aditxt [2]. - The remaining amount of USD 1,000,000 is still payable to Appili [2]. Group 2: Financial Arrangements - In connection with the termination, Appili has secured 3-month extensions on amounts due under its secured loan agreement with Long Zone Holdings Inc. and unsecured promissory notes with Bloom Burton & Co. Inc. [3]. - All amounts owed under these loans, including accrued interest, will be due on August 31, 2025 [3]. Group 3: Company Overview - Appili Therapeutics is focused on developing therapies for infectious diseases and medical countermeasures [4]. - The company aims to address urgent infections with unmet needs and is advancing a diverse range of anti-infectives, including an FDA-approved treatment for antimicrobial-resistant infections [4]. - Appili is led by a proven management team and is positioned at the forefront of the global fight against infections [4].

Core Viewpoint - Appili Therapeutics Inc. has submitted four new funding proposals totaling US$117.5 million to advance treatments for infectious diseases, aligning with public health priorities [1] Funding Opportunities - The company applied for two solicitations from the National Institute of Allergy and Infectious Diseases (NIAID), seeking US$46.3 million for a vaccine against invasive fungal infections and US$36.4 million for an antifungal monoclonal antibody targeting a rare fungal infection [2] - Additionally, two proposals were submitted to the US Medical CBRN Defense Consortium (MCDC) for a total of US$34.8 million, including US$20.1 million for a broad-spectrum treatment for viral infections and US$14.7 million for a direct-acting antiviral [3] Consortium Membership - Appili has been selected to join the MCDC, which has awarded over US$7 billion in project funding, enhancing the company's role in developing medical countermeasures [4] Previous Funding Success - The company has raised approximately US$33.2 million in prior government funding awards, which have supported the development of various pipeline programs, including ATI-1701 and LIKMEZ™ [6] Update on USAFA Awards - Appili received an update regarding its arrangement with the United States Air Force Academy (USAFA) for ATI-1701, with a total of approximately US$14 million awarded, of which US$11.6 million has been allocated for services [7][10] - A modification to the USAFA Cooperative Agreement has resulted in an increased General & Administrative overhead recovery rate, benefiting the company financially [8] Going-Private Transaction - The company is in the process of a going-private transaction with Aditxt Inc., which has received shareholder and court approvals, with an extended deadline for financing set to March 31, 2025 [11][12][13]